Ubs Group Ag Iovance Biotherapeutics, Inc. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 795,204 shares of IOVA stock, worth $8.77 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

795,204

Previous 690,880 15.1%

Holding current value

$8.77 Million

Previous $10.2 Million 37.71%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$7.78 - $14.19 $811,640 - $1.48 Million	104,324 Added 15.1%	795,204 $6.38 Million
Q1 2024 May 13, 2024	SELL	$7.59 - $17.47 $1.26 Million - $2.91 Million	-166,428 Reduced 19.41%	690,880 $10.2 Million
Q4 2023 Feb 09, 2024	BUY	$3.3 - $8.89 $2.03 Million - $5.48 Million	615,920 Added 255.16%	857,308 $6.97 Million
Q3 2023 Nov 09, 2023	SELL	$4.44 - $8.79 $1.01 Million - $2.01 Million	-228,424 Reduced 48.62%	241,388 $1.1 Million
Q2 2023 Aug 11, 2023	BUY	$5.36 - $9.06 $230,442 - $389,516	42,993 Added 10.07%	469,812 $3.31 Million
Q1 2023 May 12, 2023	SELL	$5.53 - $8.22 $2.05 Million - $3.05 Million	-370,863 Reduced 46.49%	426,819 $2.61 Million
Q4 2022 Feb 08, 2023	BUY	$5.62 - $10.0 $3.89 Million - $6.91 Million	691,443 Added 650.84%	797,682 $5.1 Million
Q3 2022 Nov 10, 2022	BUY	$9.53 - $13.11 $110,547 - $152,076	11,600 Added 12.26%	106,239 $1.02 Million
Q2 2022 Aug 10, 2022	SELL	$6.38 - $18.33 $1.69 Million - $4.86 Million	-265,107 Reduced 73.69%	94,639 $1.05 Million
Q1 2022 May 16, 2022	BUY	$12.38 - $19.1 $1.74 Million - $2.68 Million	140,209 Added 63.87%	359,746 $5.99 Million
Q4 2021 Feb 14, 2022	BUY	$16.55 - $27.63 $384,837 - $642,480	23,253 Added 11.85%	219,537 $4.19 Million
Q3 2021 Nov 15, 2021	BUY	$20.35 - $26.63 $2.72 Million - $3.56 Million	133,742 Added 213.84%	196,284 $4.84 Million
Q2 2021 Aug 13, 2021	SELL	$16.33 - $33.07 $576,546 - $1.17 Million	-35,306 Reduced 36.08%	62,542 $1.63 Million
Q1 2021 May 12, 2021	BUY	$28.67 - $52.59 $350,318 - $642,597	12,219 Added 14.27%	97,848 $3.1 Million
Q4 2020 Feb 11, 2021	BUY	$28.04 - $50.26 $382,746 - $686,049	13,650 Added 18.96%	85,629 $3.97 Million
Q3 2020 Nov 12, 2020	BUY	$27.75 - $36.3 $740,508 - $968,665	26,685 Added 58.92%	71,979 $2.37 Million
Q2 2020 Jul 31, 2020	BUY	$27.21 - $41.0 $476,038 - $717,295	17,495 Added 62.93%	45,294 $1.24 Million
Q1 2020 May 01, 2020	SELL	$19.54 - $38.85 $2.21 Million - $4.39 Million	-112,893 Reduced 80.24%	27,799 $832,000
Q4 2019 Feb 14, 2020	SELL	$17.95 - $29.41 $4.22 Million - $6.92 Million	-235,229 Reduced 62.57%	140,692 $3.89 Million
Q3 2019 Nov 14, 2019	BUY	$17.99 - $26.0 $4.39 Million - $6.35 Million	244,162 Added 185.31%	375,921 $6.84 Million
Q2 2019 Aug 14, 2019	BUY	$9.78 - $24.52 $1.19 Million - $2.98 Million	121,504 Added 1184.83%	131,759 $3.23 Million
Q1 2019 May 14, 2019	SELL	$8.41 - $11.26 $2.18 Million - $2.92 Million	-259,239 Reduced 96.19%	10,255 $98,000
Q4 2018 Feb 14, 2019	BUY	$7.51 - $11.93 $1.68 Million - $2.67 Million	223,833 Added 490.21%	269,494 $2.39 Million
Q3 2018 Nov 14, 2018	BUY	$11.25 - $17.7 $430,605 - $677,485	38,276 Added 518.29%	45,661 $513,000
Q2 2018 Aug 14, 2018	SELL	$12.45 - $16.95 $670,270 - $912,537	-53,837 Reduced 87.94%	7,385 $95,000
Q1 2018 May 15, 2018	BUY	$8.1 - $19.5 $484,590 - $1.17 Million	59,826 Added 4285.53%	61,222 $1.04 Million
Q4 2017 Feb 14, 2018	SELL	$6.65 - $9.25 $43,916 - $61,087	-6,604 Reduced 82.55%	1,396 $11,000
Q3 2017 Nov 14, 2017	SELL	$4.45 - $8.55 $4,770 - $9,165	-1,072 Reduced 11.82%	8,000 $62,000
Q2 2017 Aug 14, 2017	BUY	N/A	9,072	9,072 $67,000

Others Institutions Holding IOVA

# of Institutions

320

Shares Held

238M

Call Options Held

1.27M

Put Options Held

1.68M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.74B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account